Clinical Trial Detail

NCT ID NCT02301156
Title Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

chronic lymphocytic leukemia

Therapies

Ibrutinib + Ublituximab

Ibrutinib

Age Groups: adult senior

No variant requirements are available.